VIRX Projected Dividend Yield
Viracta Therapeutics Inc ( OTCBB : VIRX )Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on treating and preventing virus-associated cancers. Its lead product, Nana-val, combines nanatinostat and valganciclovir. Nana-val is being tested in several clinical trials, including a Phase II trial for relapsed or refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1) and a Phase Ib/II trial for recurrent or metastatic EBV+ nasopharyngeal carcinoma and other advanced EBV+ solid tumors. Viracta is also exploring its Kick and Kill approach for other virus-related cancers. 21 YEAR PERFORMANCE RESULTS |
VIRX Dividend History Detail VIRX Dividend News VIRX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |